Lantheus Holdings (Lantheus Holdings) Long-Term Capital Lease Obligation : $54 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings Long-Term Capital Lease Obligation?

Lantheus Holdings's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $54 Mil.

Lantheus Holdings's quarterly Long-Term Capital Lease Obligation increased from Sep. 2023 ($54 Mil) to Dec. 2023 ($54 Mil) but then declined from Dec. 2023 ($54 Mil) to Mar. 2024 ($54 Mil).

Lantheus Holdings's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($17 Mil) to Dec. 2022 ($25 Mil) and increased from Dec. 2022 ($25 Mil) to Dec. 2023 ($54 Mil).

Lantheus Holdings Long-Term Capital Lease Obligation Historical Data

The historical data trend for Lantheus Holdings's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings Long-Term Capital Lease Obligation Chart

Lantheus Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

17.50

16.55

25.44

54.45

Lantheus Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															24.79	31.25	54.42	54.45	54.12

Lantheus Holdings (NAS:LNTH) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Lantheus Holdings Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Lantheus Holdings (Lantheus Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (NAS:LNTH) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

0L8:Germany

Address

201 Burlington Road, South Building, Bedford, MA, USA, 01730

Website

https://www.lantheus.com

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Executives

Andrea Sabens	officer: Chief Accounting Officer	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Marshall Robert J. Jr.	officer: CFO and Treasurer	C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Paul Blanchfield	officer: Chief Commercial Officer	C/O LANTHEUS HOLDINGS, INC., 331, NORTH BILLERICA MA 01862
Mary Anne Heino	director, officer: CEO and President	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Daniel Niedzwiecki	officer: See Remarks	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Minnie Baylor-henry	director	C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Etienne Montagut	officer: See Remarks	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Sam R Leno	director	C/O BOSTON SCIENTIFIC CORPORATION, ONE BOSTON SCIENTIFIC PLACE, NATICK MA 01760
Brian A Markison	director	501 FIFTH STREET, BRISTOL TN 37620
Jean-claude Provost	officer: Chief Medical Officer	C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON RD, SOUTH BUILDING, BEDFORD MA 01730
Julie Mchugh	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Gerard Ber	director	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Carol Walker	officer: Senior Vice President, Quality	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Ying Vivian Yao	officer: Chief Human Resources Officer	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
John J. Bolla	director	C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862